{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T04:55:41Z","timestamp":1785128141835,"version":"3.55.0"},"reference-count":99,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T00:00:00Z","timestamp":1666569600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Primary membranous nephropathy (MN) is an important cause of nephrotic syndrome and chronic kidney disease (CKD) in the adult population. Although the discovery of different autoantibodies against glomerular\/podocytic antigens have highlighted the role of B cells in the pathogenesis of MN, suboptimal response or even resistance to B cell-directed therapies occurs, suggesting that other pathophysiological mechanisms are involved in mediating podocyte injury. The complement system plays an important role in the innate immune response to infection, and dysregulation of the complement system has been observed in various kidney diseases. There is compelling evidence of complement cascade activation in primary MN, with the mannose-binding lectin (MBL) and alternative pathways particularly implicated. With appropriate validation, assays of complements and associated activation products could hold promise as adjunctive tools for non-invasive disease monitoring and prognostication. While there is growing interest to target the complement system in MN, there is concern regarding the risk of infection due to encapsulated organisms and high treatment costs, highlighting the need for clinical trials to identify patients most likely to benefit from complement-directed therapies.<\/jats:p>","DOI":"10.3389\/fimmu.2022.1009864","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T13:21:06Z","timestamp":1666617666000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":27,"title":["The role of the complement system in primary membranous nephropathy: A narrative review in the era of new therapeutic targets"],"prefix":"10.3389","volume":"13","author":[{"given":"Benjamin Y. F.","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary C. W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Desmond Y. H.","family":"Yap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tak Mao","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfq665","article-title":"The incidence of primary glomerulonephritis worldwide: A systematic review of the literature","volume":"26","author":"McGrogan","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2015.07.006","article-title":"AJKD atlas of renal pathology: Membranous nephropathy","volume":"66","author":"Fogo","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1097\/mnh.0000000000000697","article-title":"Membranous nephropathy: Current understanding of various causes in light of new target antigens","volume":"30","author":"Ronco","year":"2021","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2019.09.014","article-title":"Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy","volume":"97","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2020.05.030","article-title":"Semaphorin 3b-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients","volume":"98","author":"Sethi","year":"2020","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409354","article-title":"Thrombospondin type-1 domain-containing 7a in idiopathic membranous nephropathy","volume":"371","author":"Tomas","year":"2014","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2020081165","article-title":"Protocadherin 7-associated membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2018080852","article-title":"Exostosin 1\/Exostosin 2-associated membranous nephropathy","volume":"30","author":"Sethi","year":"2019","journal-title":"J Am Soc Nephrol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2018.10.021","article-title":"Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies","volume":"95","author":"Bobart","year":"2019","journal-title":"Kidney Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfab116","article-title":"Monitoring anti-PLA2R antibody titres to predict the likelihood of spontaneous remission of membranous nephropathy","volume":"14","author":"Jatem-Escalante","year":"2021","journal-title":"Clin Kidney J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/bor.0000000000000633","article-title":"Complement, infection, and autoimmunity","volume":"31","author":"Conigliaro","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.06230614","article-title":"Molecules great and small: The complement system","volume":"10","author":"Mathern","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1111\/imr.12468","article-title":"A journey through the lectin pathway of complement-MBL and beyond","volume":"274","author":"Garred","year":"2016","journal-title":"Immunol Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2019.101341","article-title":"Regulation of regulators: Role of the complement factor H related proteins","volume":"45","author":"Cserhalmi","year":"2019","journal-title":"Semin Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100238","article-title":"The role of properdin in C5 convertase activity and C5b-9 formation in the complement alternative pathway","volume":"207","author":"Michels","year":"2021","journal-title":"J Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1084\/jem.148.4.1044","article-title":"Human C4-binding protein. ii. role in proteolysis of C4b by C3b-inactivator","volume":"148","author":"Fujita","year":"1978","journal-title":"J Exp Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1084\/jem.194.11.1609","article-title":"Complement 1 inhibitor is a regulator of the alternative complement pathway","volume":"194","author":"Jiang","year":"2001","journal-title":"J Exp Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-62703-724-2_18","article-title":"Factor H related proteins","volume":"1100","author":"J\u00f3zsi","year":"2014","journal-title":"Methods Mol Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-02-205641","article-title":"Factor H related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation","volume":"114","author":"Heinen","year":"2009","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.molimm.2006.06.019","article-title":"Alternative roles for CD59","volume":"44","author":"Kimberley","year":"2007","journal-title":"Mol Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.1995.tb02289.x","article-title":"Complement inhibition by human vitronectin involves non-heparin binding domains","volume":"101","author":"Sheehan","year":"1995","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.151.4.2159","article-title":"Clusterin, the human apolipoprotein and complement inhibitor, binds to complement C7, C8 beta, and the b domain of C9","volume":"151","author":"Tschopp","year":"1993","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.154.7.3437","article-title":"Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive heymann nephritis","volume":"154","author":"Quigg","year":"1995","journal-title":"J Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21020525","article-title":"A narrative review on C3 glomerulopathy: A rare renal disease","volume":"21","author":"Schena","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semnephrol.2015.08.006","article-title":"The complement system in lupus nephritis","volume":"35","author":"Birmingham","year":"2015","journal-title":"Semin Nephrol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nrneph.2017.37","article-title":"Complement in ANCA-associated vasculitis: Mechanisms and implications for management","volume":"13","author":"Chen","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-021-00882-9","article-title":"Complement activation in IgA nephropathy","volume":"43","author":"Medjeral-Thomas","year":"2021","journal-title":"Semin Immunopathol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.914382","article-title":"Identification of hub genes and immune-related pathways for membranous nephropathy by bioinformatics analysis","volume":"13","author":"Cai","year":"2022","journal-title":"Front Physiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12882-018-1011-5","article-title":"Clinical implications of pathological features of primary membranous nephropathy","volume":"19","author":"Zhang","year":"2018","journal-title":"BMC Nephrol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.01.018","article-title":"Proteomic analysis of complement proteins in membranous nephropathy","volume":"5","author":"Ravindran","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1172\/jci109987","article-title":"A new role for complement in experimental membranous nephropathy in rats","volume":"66","author":"Salant","year":"1980","journal-title":"J Clin Invest"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00305.x","article-title":"Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy","volume":"64","author":"Saran","year":"2003","journal-title":"Kidney Int"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1324804","article-title":"Anti-PLA2R1 antibodies containing sera induce in vitro cytotoxicity mediated by complement activation","volume":"2019","author":"Lateb","year":"2019","journal-title":"J Immunol Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/jci116722","article-title":"Differential expression of complement C3 and C4 in the human kidney","volume":"92","author":"Welch","year":"1993","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12882-019-1509-5","article-title":"Complement activation products in the circulation and urine of primary membranous nephropathy","volume":"20","author":"Zhang","year":"2019","journal-title":"BMC Nephrol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2021101384","article-title":"Complement C3a and C3a receptor activation mediates podocyte injuries in the mechanism of primary membranous nephropathy","volume":"33","author":"Gao","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1681\/asn.v114700","article-title":"Complement activation products in the urine from proteinuric patients","volume":"11","author":"Morita","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.11.032","article-title":"Establishing a case for anti-complement therapy in membranous nephropathy","volume":"6","author":"Ayoub","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B42","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.137.5.1511","article-title":"The membrane attack complex in complement-mediated glomerular epithelial cell injury: Formation and stability of C5b-9 and C5b-7 in rat membranous nephropathy","volume":"137","author":"Cybulsky","year":"1986","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1172\/jci112408","article-title":"Complement-induced glomerular epithelial cell injury","volume":"77","author":"Cybulsky","year":"1986","journal-title":"Role Membrane Attack Complex Rat Membranous Nephropathy J Clin Invest"},{"key":"B44","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.143.2.546","article-title":"Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy","volume":"143","author":"Kerjaschki","year":"1989","journal-title":"J Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01433","article-title":"Alternative pathway is essential for glomerular complement activation and proteinuria in a mouse model of membranous nephropathy","volume":"9","author":"Luo","year":"2018","journal-title":"Front Immunol"},{"key":"B46","article-title":"Depletion of C6 prevents development of proteinuria in experimental membranous nephropathy in rats","volume":"135","author":"Baker","year":"1989","journal-title":"Am J Pathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1989.8","article-title":"Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat","volume":"35","author":"Schulze","year":"1989","journal-title":"Kidney Int"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/bj2640001","article-title":"Complement membrane attack on nucleated cells: Resistance, recovery and non-lethal effects","volume":"264","author":"Morgan","year":"1989","journal-title":"Biochem J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1989.257.5.F826","article-title":"Complement C5b-9 complex activates phospholipases in glomerular epithelial cells","volume":"257","author":"Cybulsky","year":"1989","journal-title":"Am J Physiol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00932.x","article-title":"Complement-induced phospholipase A2 activation in experimental membranous nephropathy","volume":"57","author":"Cybulsky","year":"2000","journal-title":"Kidney Int"},{"key":"B51","first-page":"45","article-title":"A role for thromboxane in complement-mediated glomerular injury","volume":"128","author":"Cybulsky","year":"1987","journal-title":"Am J Pathol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.165498","article-title":"Cytochrome P450 2B1 mediates complement-dependent sublytic injury in a model of membranous nephropathy","volume":"285","author":"Liu","year":"2010","journal-title":"J Biol Chem"},{"key":"B53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/s41419-022-04737-5","article-title":"Complement induces podocyte pyroptosis in membranous nephropathy by mediating mitochondrial dysfunction","volume":"13","author":"Wang","year":"2022","journal-title":"Cell Death Dis"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1681\/asn.v7112314","article-title":"Complement synthesis in the injured kidney: Does it have a role in immune complex glomerulonephritis","volume":"7","author":"Sacks","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"B55","article-title":"Intraglomerular C3 synthesis in rats with passive Heymann nephritis","volume":"151","author":"Sasaki","year":"1997","journal-title":"Am J Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2000.00812.x","article-title":"Renal C3 synthesis in idiopathic membranous nephropathy: Correlation to urinary C5b-9 excretion","volume":"57","author":"Montinaro","year":"2000","journal-title":"Kidney Int"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.90313.2008","article-title":"Complement activation by tubular cells is mediated by properdin binding. Am J Physiol Renal Physiol","volume":"295","author":"Gaarkeuken","year":"2008"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2004.02411.x","article-title":"The membrane attack complex, C5b-9, up regulates collagen gene expression in renal tubular epithelial cells","volume":"136","author":"Abe","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-009-1439-8","article-title":"IgG subclasses and complement pathway in segmental and global membranous nephropathy","volume":"25","author":"Segawa","year":"2010","journal-title":"Pediatr Nephrol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2018.06.050","article-title":"Clinical and prognostic significance of glomerular C1q deposits in primary MN","volume":"485","author":"Zhang","year":"2018","journal-title":"Clin Chim Acta"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/jci140453","article-title":"Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy","volume":"131","author":"Haddad","year":"2021","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2022.02.002","article-title":"Comparison of complement pathway activation in autoimmune glomerulonephritis","volume":"7","author":"Genest","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"BSR20180131","DOI":"10.1042\/bsr20180131","article-title":"Human anti-thrombospondin type 1 domain-containing 7a antibodies induce membranous nephropathy through activation of lectin complement pathway","volume":"38","author":"Wang","year":"2018","journal-title":"Biosci Rep"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfx235","article-title":"Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy","volume":"33","author":"Hayashi","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12026-016-8790-1","article-title":"Igg4 anti-phospholipase A2 receptor might activate lectin and alternative complement pathway meanwhile in idiopathic membranous nephropathy: An inspiration from a cross-sectional study","volume":"64","author":"Yang","year":"2016","journal-title":"Immunol Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1159\/000486552","article-title":"Mannose-binding Lectin2 gene polymorphism and IgG4 in membranous nephropathy","volume":"139","author":"Costa","year":"2018","journal-title":"Nephron"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2015101155","article-title":"Phospholipase A2 receptor-related membranous nephropathy and mannan-binding lectin deficiency","volume":"27","author":"Bally","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.952235","article-title":"The alternative pathway is necessary and sufficient for complement activation by anti-THSD7A autoantibodies, which are predominantly Igg4 in membranous nephropathy","volume":"13","author":"Manral","year":"2022","journal-title":"Front Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-020-02698-2","article-title":"The correlation of anti-\u03b22-Glycoprotein I antibody with complement activation in patients with idiopathic membranous nephropathy","volume":"53","author":"Zhang","year":"2021","journal-title":"Int Urol Nephrol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185x.13733","article-title":"Association between antiphospholipid antibodies and factor Bb in lupus nephritis patients with glomerular microthrombosis","volume":"22","author":"Zhou","year":"2019","journal-title":"Int J Rheum Dis"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1159\/000079174","article-title":"Glomerular deposition and urinary excretion of complement factor H in idiopathic membranous nephropathy","volume":"97","author":"Endo","year":"2004","journal-title":"Nephron Clin Pract"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1681\/asn.v1081689","article-title":"Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis","volume":"10","author":"Raats","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.16631020","article-title":"Limited significance of antifactor H antibodies in patients with membranous nephropathy","volume":"16","author":"Sethi","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1805857","article-title":"Factor H autoantibodies and membranous nephropathy","volume":"379","author":"Seikrit","year":"2018","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.5414\/cn110479","article-title":"Association between anti-complement factor H antibodies and renal outcome in primary membranous nephropathy","volume":"96","author":"Kagaya","year":"2021","journal-title":"Clin Nephrol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2001.060003900.x","article-title":"Glomerular complement regulation is overwhelmed in passive heymann nephritis","volume":"60","author":"Cunningham","year":"2001","journal-title":"Kidney Int"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3265\/Nefrologia.pre2012.Feb.11224","article-title":"C4d as a diagnostic tool in membranous nephropathy","volume":"32","author":"Espinosa-Hern\u00e1ndez","year":"2012","journal-title":"Nefrologia"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.14670\/hh-26.1391","article-title":"C4d immunohistochemical staining is a sensitive method to confirm immunoreactant deposition in formalin-fixed paraffin-embedded tissue in membranous glomerulonephritis","volume":"26","author":"Val-Bernal","year":"2011","journal-title":"Histol Histopathol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1038\/s41598-019-42689-7","article-title":"Low serum C3 level, high neutrophil-Lymphocyte-Ratio, and high platelet-Lymphocyte-Ratio all predicted poor long-term renal survivals in biopsy-confirmed idiopathic membranous nephropathy","volume":"9","author":"Tsai","year":"2019","journal-title":"Sci Rep"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00915-w","article-title":"Clinical significance of glomerular C3 deposition in primary membranous nephropathy","volume":"34","author":"Oto","year":"2021","journal-title":"J Nephrol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1992.143","article-title":"Urinary C3dg and C5b-9 indicate active immune disease in human membranous nephropathy","volume":"41","author":"Brenchley","year":"1992","journal-title":"Kidney Int"},{"key":"B82","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/oxfordjournals.ndt.a092491","article-title":"The temporal relationship between urinary C5b-9 and C3dg and clinical parameters in human membranous nephropathy","volume":"8","author":"Coupes","year":"1993","journal-title":"Nephrol Dial Transplant"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1995.496","article-title":"Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy","volume":"48","author":"Kon","year":"1995","journal-title":"Kidney Int"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/12.12.2576","article-title":"Antiproteinuric effect of angiotensin-converting enzyme inhibition and C5b-9 urinary excretion in membranous glomerulonephritis","volume":"12","author":"Praga","year":"1997","journal-title":"Nephrol Dial Transplant"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/ki.1991.326","article-title":"Measurement of SC5b-9 in urine in patients with the nephrotic syndrome","volume":"40","author":"Ogrodowski","year":"1991","journal-title":"Kidney Int"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2362.2003.01153.x","article-title":"Urinary excretion of complement C3d in patients with renal diseases","volume":"33","author":"Branten","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"B87","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000186513","article-title":"Urinary excretion of terminal complement complexes in glomerular disease","volume":"59","author":"Kusunoki","year":"1991","journal-title":"Nephron"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 guideline for the management of glomerular diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.12.035","article-title":"Rituximab in membranous nephropathy","volume":"6","author":"Gauckler","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2016070776","article-title":"A proposal for a serology-based approach to membranous nephropathy","volume":"28","author":"De Vriese","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2006040377","article-title":"How does proteinuria cause progressive renal damage","volume":"17","author":"Abbate","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"B95","article-title":"Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (Imn): Preliminary baseline and pharmacokinetic (Pk)\/Pharmacodynamic (Pd) data","volume":"13","author":"Appel","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820892116","article-title":"Small-molecule factor B inhibitor for the treatment of complement-mediated diseases","volume":"116","author":"Schubart","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B97","doi-asserted-by":"publisher","first-page":"S236","DOI":"10.1016\/j.ekir.2022.01.577","article-title":"Pos-546 efficacy and safety of iptacopan in IgA nephropathy: Results of a randomized double-blind placebo-controlled phase 2 study at 6 months","volume":"7","author":"Barratt","year":"2022","journal-title":"Kidney Int Rep"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2019.09.004","article-title":"Eculizumab and beyond: The past, present, and future of complement therapeutics","volume":"33","author":"Patriquin","year":"2019","journal-title":"Transfus Med Rev"},{"key":"B99","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1009864\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T20:25:02Z","timestamp":1678393502000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.1009864\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,24]]},"references-count":99,"alternative-id":["10.3389\/fimmu.2022.1009864"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.1009864","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,24]]},"article-number":"1009864"}}